Two of Israel’s leading financial news outlets, Globes and The Marker, reported on Sunday that Blavatnik has been examining a large share purchase in Teva, whose stock price hit a 17-year-low last week after the company again cut …
If you have even a hint of a contrarian personality, you should look no further than the pharmaceutical industry. Thanks to various scandals and controversies like the one impacting Valeant Pharmaceuticals Intl Inc (NYSE:VRX), plenty of big …
Teva Pharmaceutical Industries Ltd. shares rose 1.6% in premarket trade Thursday after the company reported a first-quarter profit beat and revenue miss. Earnings for the latest quarter rose to $580 million, or 57 cents per share, from …
As a result of its acceptance of the shares tendered in the Offer, Teva has acquired a sufficient number of shares of NuPathe’s common stock to close the merger of Merger Sub with and into NuPathe without the affirmative vote of …
Don’t buy the pain meds Citi is prescribing in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). In our view, it’s too late to fill that order and this is a better occasion to take on a pick-me-up, contrarian position in TEVA with a bullish …
The strike forced closure of Ben-Gurion airport, banks, the Tel Aviv Stock Exchange and all government ministries. Teva is one of the biggest employers in Israel. Avi Nissenkorn, head of the Histadrut, the umbrella organization for all public …
The company’s shares are owned by so many pension funds that it is known informally as the people’s stock. Today, many of those people are furious. Management missteps and tectonic shifts in the pharmaceutical business have …
For the quarter, Teva wound up reporting $5.69 billion in sales, which was notably higher than $5.04 billion reported in the year-ago period. However, the growth in sales came predominantly from its acquisition of Actavis, making it the largest …
Teva's depositary receipts added 7 cents to close at $31.23. Each depositary receipt represents one share of Teva common stock. Manoj K. Garg, senior analyst at American Technology Research in Greenwich, Conn., said the …
Teva Pharmaceutical Industries Limited TEVA reported third-quarter 2017 earnings of $1.00 per share, which missed the Zacks Consensus Estimate of $1.05 per share by 4.8% and declined 24% year over year. Revenues of $5.61 billion …